•  
  •  
 

Abstract

Background: Psoriasis is a dermatological condition influenced by genetic and epigenetic factors, environmental triggers, as well as immune responses. Genomics refers to the study of individual genes (genomes) and their interactions with environmental influences. In the context of psoriasis genomics, the interplay between genetic predisposition and environmental factors contributes to the manifestation and variations of the disease. With advancements in molecular genotyping technology and genome-wide association studies (GWASs), researchers have identified 50 genetic markers linked to psoriasis.

Discussion: Several genetic loci associated with psoriasis have been identified, including PSORS 1-15. The genetics of psoriasis is also linked to its onset, precipitating factors, associated comorbidities, and clinical variations. Advances in psoriasis genomics are leading to more targeted and innovative treatment approaches. The latest therapeutic developments for psoriasis mainly focus on the interleukin-23 (IL-23)/T-helper 17 (Th17) pathways.

Conclusion: The development of GWASs provides new knowledge about psoriasis, including its pathogenesis and specific treatments.

References

  1. Nedoszytko B, Szczerkowska-Dobosz A, Stawczyk-Macieja M, et al. Pathogenesis of psoriasis in the “omic” era. Part II. Genetic, genomic and epigenetic changes in psoriasis. Postepy Dermatol Alergol. 2020;37(3):283–98.
  2. Huang YH, Kuo CF, Huang LH, Hsieh MY. Familial aggregation of psoriasis and co-aggregation of autoimmune diseases in affected families. J Clin Med. 2019:8(1):1–11.
  3. Uffelmann E, Huang QQ, Munung NS, et al. Genome-wide association studies. Nat Rev Methods Primers. 2021;1(1):1–21.
  4. Nair RP, Stuart PE, Nistor I, et al. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. Am J Hum Genet. 2006;78(5):827–51.
  5. Jordan CT, Cao L, Roberson ED, et al. PSORS2 is due to mutations in CARD14. Am J Hum Genet. 2012;90(5):784–95.
  6. Ran D, Cai M, Zhang X. Genetics of psoriasis: A basis for precision medicine. Precis Clin Med. 2019;2(2):120–30.
  7. Wang WM, Li F, Jin HZ. Role of interferon regulatory factor-mediated signaling in psoriasis. Int J Med Sci. 2021;18(16):3794–9.
  8. Naslund-Koch C, Bojesen SE, Vedel-Krogh S, Skov L. Smoking is an independent but not a causal risk factor for moderate to severe psoriasis: A Mendelian randomization study of 105,912 individuals. Front Immunol. 2023;14:1–8.
  9. Tsoi LC, Stuart PE, Tian C, et al. Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants. Nat Commun. 2017;8(1):1–8.
  10. Dand N, Mahil S, Capon F, Smith C, Simpson M, Barker J. Psoriasis and genetics. Acta Derm Venereol. 2020;100(3):54–64.
  11. Owczarczyk-Saczonek A, Purzycka-Bohdan D, Nedoszytko B, et al. Pathogenesis of psoriasis in the “omic” era. Part III. Metabolic disorders, metabolomics, nutrigenomics in psoriasis. Postepy Dermatol Alergol. 2020;37(4):452–67.
  12. Chen L, Tsai TF. HLA-Cw6 and psoriasis. Br J Dermatol. 2018;178(4):854–62.
  13. Sylviningrum T, Putranti IO, Sari OP, Arjadi F, Sudibyo ES, Manik SN. Association between HLA-CW6 allele expression and characteristics of Javanese ethnic psoriasis patients in Indonesia. Med J Indones. 2019;28(4):370–4.
  14. Berki DM, Liu L, Choon SE, et al. Activating CARD14 mutations are associated with generalized pustular psoriasis but rarely account for familial recurrence in psoriasis vulgaris. J Invest Dermatol. 2015;135(12):2964–70.
  15. Naik HB, Cowen EW. Autoinflammatory pustular neutrophilic diseases. Dermatol Clin. 2013;31(3):405–25.
  16. Hussain S, Berki DM, Choon SE, et al. IL36RN mutations define a severe autoinflammatory phenotype of generalized pustular psoriasis. J Allergy Clin Immunol. 2015;135(4):1067–70.
  17. Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143(3):1021–6.
  18. Bowes J, Ashcroft J, Dand N, et al. Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Ann Rheum Dis. 2017;76(10):1774–9.
  19. Köse B, Uzlu D, Erdöl H. Psoriasis and uveitis. Int Ophthalmol. 2022;42(7):2303–10.
  20. Budu-Aggrey A, Brumpton B, Tyrrell J, et al. Evidence of a causal relationship between body mass index and psoriasis: A mendelian randomization study. PLoS Med. 2019;16(1):1–18.
  21. Abramczyk R, Queller JN, Rachfal AW, Schwartz SS. Diabetes and psoriasis: Different sides of the same prism. Diabetes Metab Syndr Obes. 2020;13:3571–7.
  22. Ellinghaus D, Jostins L, Spain SL, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet. 2016;48(5):510–8.
  23. Patel HA, Revankar RR, Pedroza ST, Graham S, Feldman SR. The genetic susceptibility to psoriasis and the relationship of linked genes to our treatment options. Int J Mol Sci. 2023;24(15):1–11.
  24. Puig L, Julià A, Marsal S. The pathogenesis and genetics of psoriasis. Actas Dermosifiliogr. 2014;105(6):535–45.
  25. Dand N, Duckworth M, Baudry D, et al. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. J Allergy Clin Immunol. 2019;143(6):2120–30.

Download

Share

COinS